Zai Lab Advances ZL-1310 in Phase 1b/2 Trial for Advanced Solid Tumors
Zai Lab announced an update on its Phase 1b/2 clinical study of ZL-1310, an experimental drug designed to treat advanced solid tumors with limited treatment options.
Zai Lab Ltd announced an update on their ongoing clinical study of ZL-1310, an experimental cancer drug being tested in advanced solid tumors. The study, officially titled "A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors," aims to test the new cancer drug in advanced solid tumors and seeks early signals on safety and anti-tumor activity.
The intervention is a single experimental drug called ZL-1310, given on its own as a treatment. It is designed to slow or shrink solid tumors that have limited options, positioning it as a potential new asset in the company's cancer portfolio.
The trial is an interventional Phase 1b/2 study with one treatment arm and no randomization, so all patients receive ZL-1310. It is open-label and not blinded, and the main goal is to evaluate treatment impact and safety in real patients rather than compare against a control.
The study started recruiting after submission on February 24, 2025, marking the formal launch of clinical work. The latest update on February 10, 2026, shows the trial is still active, but primary and final completion dates are not yet posted. The study remains ongoing and updated, with further details available on the ClinicalTrials portal.